REGULATORY INTELLIGENCE
Cybersecurity and MedTech: Integrating Security into the Quality System
For regulatory affairs professionals, cybersecurity in medical technology is no longer an IT problem or a purely commercial differentiator. It is integral to device safety, performance, and regulatory compliance. As devices become increasingly connected and software-defined, vulnerabilities translate directly into patient harm, compromised clinical workflows, and regulatory exposure. The regulatory lens reframes cybersecurity into the familiar language of quality: design controls, risk management, supplier oversight, postmarket surveillance, and change control.
Governance: The Starting Point for QMS Integration
Integrating cybersecurity into the QMS begins with governance and a single-source expectation that security activities map into existing QMS processes. RA professionals should advocate for governance structures that cross design, cybersecurity engineering, IT, clinical, legal, and safety teams — defining who owns the threat model, who authorizes mitigations, and who communicates with regulators and customers.
Design Controls and Secure Development
Cybersecurity must be embedded in the product development lifecycle. Requirements traceability should include security requirements derived from threat modeling and foreseeable misuse scenarios. IEC 62304–aligned software processes, combined with secure development practices — threat modeling, static and dynamic analysis, code review, and penetration testing — become the verification basis for regulatory claims.
Regulatory expectation Regulatory reviewers expect documented traceability from identified threats to implemented mitigations and test evidence demonstrating effectiveness. This traceability is a core inspection focus under both FDA premarket review and EU MDR notified body audits.
Risk Management and Clinical Context
Risk management must explicitly incorporate cyber-originated hazards and their clinical consequences. Availability and integrity failures — denial of service, spoofed inputs, corrupted firmware — can cause clinical harm. The risk management file should quantify or qualitatively assess exploitability and clinical impact, and justify acceptance criteria. Regulatory scrutiny focuses on the process that links cyber vulnerabilities to residual clinical risk.
Supplier and Third-Party Component Control
Modern devices depend heavily on open-source libraries, commercial off-the-shelf components, and cloud services. The QMS must extend supplier qualification, component inventory, and software bill of materials management to cover the full software supply chain. Supplier agreements should address security update obligations, vulnerability disclosure protocols, and end-of-support timelines.
Postmarket Surveillance and Change Control
The QMS must maintain processes for ongoing vulnerability monitoring, coordinated disclosure, patch development, and change control for security updates. Postmarket surveillance data — including field reports, security researcher disclosures, and threat intelligence — should feed back into the risk management file systematically.